Search

Your search keyword '"Anna Parfieniuk-Kowerda"' showing total 43 results

Search Constraints

Start Over You searched for: Author "Anna Parfieniuk-Kowerda" Remove constraint Author: "Anna Parfieniuk-Kowerda"
43 results on '"Anna Parfieniuk-Kowerda"'

Search Results

1. Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination

3. Effect of antiviral and immunomodulatory treatment on a cytokine profile in patients with COVID-19

4. Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens

5. High CD163 Expression on Classical Monocytes Is Associated with Immune Control of HBV Infection in Noncirrhotic Patients

6. The Role of Th17 Response in COVID-19

7. Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease

8. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

9. Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland

10. Effectiveness of pangenotypic retreatment of chronic hepatitis C after prior failure of pangenotypic therapies

11. Implementation of the web-based calculator estimating odds ratio of severe COVID-19 for unvaccinated individuals in a country with high coronavirus-related death toll

12. High CD163 Expression on Classical Monocytes Is Associated with Immune Control of HBV Infection in Noncirrhotic Patients

13. Implementation of the User-Friendly Odds Ratio Calculator for Unvaccinated Individuals in a Country with a High COVID-19 Death Toll

14. Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection

15. Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity

16. Chronic hepatitis B virus infection is associated with decreased serum 25(OH)D concentration in non-cirrhotic patients

17. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics

18. The Role of Th17 Response in COVID-19

19. The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease

20. The occurrence of autoantibodies in patients with chronic HCV infection, including patients dialyzed and after kidney transplantation

21. Review article Immune regulation and viral diversity as correlates of natural and treatment induced immune control in persistent hepatitis B virus (HBV) infection

22. Occurrence and clinical characteristics of hepatocellular carcinoma in the north-eastern Poland

23. Serum Concentrations of Th17-Associated Interleukins and Autoimmune Phenomena are Associated with the Degree of Liver Damage in Alcoholic Liver Disease

24. Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease

26. Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection

29. Influence of HCV and HIV on development of cryoglobulinemia

30. Prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders

32. HBV mutations associated with lamivudine therapy

34. Emerging treatments for hepatitis C

35. Assessment of serum IGF-1 and adipokines related to metabolic dysfunction in HIV-infected adults

36. [Occurrence of autoantibodies in patients with alcoholic liver disease]

37. Serum cytochrome c and m30-neoepitope of cytokeratin-18 in chronic hepatitis C

38. Exacerbation of chronic hepatitis B during chemotherapy due to testicular seminoma

39. Treatment of chronic hepatitis C in a patient with Fanconi anaemia

Catalog

Books, media, physical & digital resources